Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05557695 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom

Name: Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom — clinical trial record (NCT05557695)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: EPIC

StatusRecruiting

PhaseNot specified

SponsorAstraZeneca

Started2022-10-17

View on ClinicalTrials.gov ↗

This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with chronic lymphocytic leukaemia receiving acalabrutinib in the United Kingdom (the EPIC study). Physicians treating chronic lymphocytic leukaemia patients with acalabrutinib, where the patients started treatment as part of the acalabrutinib Early Access Programme (EAP), will be invited to recruit patients. Clinical data will be extracted from the patients' clinical records in line with local laws. Data from this study will provide UK-specific real-world data on patients who were started on acalabrutinib as part of the UK acalabrutinib EAP.

Amendment history 1 change detected by DataLookout

2026-09-10

Enrollment reduced: 350 → 287 participants

Trial Details

NCT Number	NCT05557695
Lead Sponsor	AstraZeneca Collaborators: UKCLL Forum
Conditions	Chronic Lymphocytic Leukemia, CLL
Enrollment	287 participants
Start Date	2022-10-17
Primary Completion	2027-04-01 (estimated)
Study Completion	2027-04-01 (estimated)
Updated on ClinicalTrials.gov	2026-09-09